Navigation Links
Sanofi-aventis Sends Letter to Genzyme Seeking Clarification on Potential Board Actions
Date:11/8/2010

PARIS, Nov. 8, 2010 /PRNewswire/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that it has sent a letter to Genzyme Corporation (Nasdaq: GENZ) requesting that Genzyme clarify its position on a number of potential Board actions raised in Genzyme's Schedule 14D-9.

Sanofi-aventis' letter also notes that it is encouraged by Genzyme's decision to "probe and evaluate alternatives" including contacting third parties but observes that sanofi-aventis has not been contacted by Genzyme or its advisors. Sanofi-aventis continues to remain interested in working with Genzyme on a constructive basis and is committed to a mutually agreeable transaction.  

Below is the full text of the letter that was sent to Genzyme, which is also being filed with the U.S. Securities and Exchange Commission.November 8, 2010VIA EMAIL, TELECOPIER AND DHLMr. Henri TermeerChairman, President and Chief Executive OfficerGenzyme Corporation500 Kendall StreetCambridge, Massachusetts 02147USADear Henri,

Now that Genzyme's third-quarter earnings have been released, you have had the opportunity to speak to shareholders regarding Genzyme's business and prospects (including the detailed presentation to analysts and investors on October 22) and the market has had a chance to digest and react to all of this information, we would again like to request that you meet with us to discuss our proposal to acquire Genzyme.  We continue to believe that our proposal is compelling for your shareholders and would provide them with immediate and substantial value that reflects the potential of Genzyme's business and pipeline.  

You have publicly disclosed that Genzyme's Board has authorized management and the company's advisors to "probe and evaluate alternatives" for Genzyme and its assets, inclu
'/>"/>

SOURCE sanofi-aventis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Covance and sanofi-aventis Finalize Agreements for 10-year Strategic R&D Alliance
2. Sanofi-aventis to Acquire BMP Sunstone Creating a Strong Consumer Healthcare Platform in China
3. Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis
4. Sanofi-aventis Commences Tender Offer to Acquire All Outstanding Shares of Genzyme for $69 per Share in Cash
5. Covance and Sanofi-Aventis Sign Definitive Agreements for 10-Year Strategic R&D Alliance
6. European Hospital Anticoagulant Market Dominated by Sanofi-Aventiss Clexane
7. Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile
8. Sanofi-aventis Announces Non-Binding Offer to Acquire Genzyme
9. Sanofi-Aventis and Novalar File Marketing Authorization Application for OraVerse® in Five Key European Countries
10. Oramed Pharmaceuticals and sanofi-aventis Enter Into an Agreement for the Insulin Supply of Orameds Oral Insulin Capsules
11. Sanofi-aventis Successfully Completes The Acquisition of Chattem, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014   Ventana Medical Systems, Inc.  (Ventana), ... has entered into an agreement with Merck KGaA, Darmstadt, ... Serono in the United States ... Merck KGaA,s biopharmaceutical division on the development and commercialization ... using Ventana,s proprietary diagnostic assays. In alignment with Merck ...
(Date:7/10/2014)... , July 10, 2014 Decision Resources Group ... of the U.S. Food and Drug Administration,s (FDA) approval ... binder Velphoro, which was approved by the FDA in ... kidney disease (CKD) patients on dialysis. Other ... Nephrology (US) Q2 2014 : ...
(Date:1/15/2014)...  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the ... Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) ... in order to treat dental impairments, for tooth restoration ...
Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3
(Date:7/13/2014)... Recently, MyDressCity.com, one of the most popular ... has released its new range of elegant Quinceanera ... available at discounted prices. Worldwide clients can enjoy this ... the company’s online shop, there are plenty of beautiful ... with great materials. MyDressCity.com’s hot items are prom gowns, ...
(Date:7/13/2014)... A noninvasive optical imaging device developed at ... later occur in the brain and are a ... results from investigators conducting a clinical trial in ... July 15 in an oral presentation at the ... They also were invited by conference organizers to ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Wright & ... trial has been scheduled in July of 2015, in ... Lipitor lawsuits are in the discovery process in ... M. Gergel is presiding over the multidistrict litigation (MDL). ... on behalf of individuals who allege that they took ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 ECS ... who commented, “As a parent of a special needs ... need in the Seattle community for contemporary special education ... an important alternative to students and families in the ... practices and environment for special education. We welcome the ...
(Date:7/13/2014)... 13, 2014 According to The Peripheral ... a comprehensive program that teaches people how to deal ... without medications. This program also provides people with ... peripheral neuropathy , including numbness, prickling, burning, and intense ... that this home treatment program can help people eliminate ...
Breaking Medicine News(10 mins):Health News:Cheap Elegant Quinceanera Dresses Unveiled by MyDressCity.com 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4Health News:New Private School, Emerald City School, Founded in Downtown Seattle Now Accepting 1st to 6th Grade Students Who Learn Differently 2Health News:The Peripheral Neuropathy Program Review Exposes Randall Labrum's Peripheral Neuropathy Treatment Program – Vkool.com 2Health News:The Peripheral Neuropathy Program Review Exposes Randall Labrum's Peripheral Neuropathy Treatment Program – Vkool.com 3
... do minor behavior problems and experiences early in life ... group of researchers has found that the answer may ... experiences lead to behaviors and new experiences that lead ... behavior. , The researchers found that children who had ...
... revenue exceeds $10 billion, COVINGTON, Ky. and ... ASH ) today completed its acquisition of Hercules,Incorporated, ... the world,s most essential needs and industries. Each ... $18.60 in cash and 0.093 of a,share of ...
... ... Business Assets, WAYNE, Pa., Nov. 13 Escalon Medical Corp.,(Nasdaq: ... ended,September 30, 2008., For the first quarter of fiscal 2009, ... fiscal 2007. This,included product revenue of $8,669,000 for the first quarter ...
... a leading,international manufacturer, marketer, and supplier of protective ... financial,results for the third quarter of 2008., ... were $265.2 million, an,increase of 8.2% over net ... of,2007. Excluding the impact of favorable foreign currency ...
... Inc. (Nasdaq: AMLN ) will be presenting at ... Wednesday, November,19, 2008 at 8:30 a.m. ET. Daniel M. ... be providing a corporate overview., The live presentation ... made,available following the event. The Web cast and recording ...
... N.J., Nov. 13 Pharmos Corporation,(Nasdaq: PARS ) ... Market ("Nasdaq") on November 11, 2008 that the Company ... requires the,Company to have a minimum of $2,500,000 in ... $500,000 of net income,from continuing operations for the most ...
Cached Medicine News:Health News:Cascading effect of even minor early problems may explain serious teen violence 2Health News:Ashland Completes Acquisition of Hercules 2Health News:Ashland Completes Acquisition of Hercules 3Health News:Ashland Completes Acquisition of Hercules 4Health News:Ashland Completes Acquisition of Hercules 5Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 2Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 3Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 4Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 5Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 6Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 7Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 8Health News:Pregis Announces Third Quarter 2008 Financial Results 2Health News:Pregis Announces Third Quarter 2008 Financial Results 3Health News:Pregis Announces Third Quarter 2008 Financial Results 4Health News:Pregis Announces Third Quarter 2008 Financial Results 5Health News:Pregis Announces Third Quarter 2008 Financial Results 6Health News:Pregis Announces Third Quarter 2008 Financial Results 7Health News:Pregis Announces Third Quarter 2008 Financial Results 8Health News:Pregis Announces Third Quarter 2008 Financial Results 9Health News:Pregis Announces Third Quarter 2008 Financial Results 10Health News:Pregis Announces Third Quarter 2008 Financial Results 11Health News:Pregis Announces Third Quarter 2008 Financial Results 12Health News:Pharmos Corporation Announces Receipt of Nasdaq Noncompliance Letter 2
... Capture vital signs faster, easier, and ... LXi, the latest innovation in multi-parameter ... Spot LXi, you get more parameters ... flexibility to customize it to meet ...
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Medicine Products: